By: W. Lybaert MD, C. Jacobs MD, C. Fontaine MD, L. Mortier MD, S. Derijcke MD, T. Wessels MD, A. Aerssens MD
In recent years, our armamentarium for oncological diseases has rapidly evolved; treatment modalities include surgery, radiotherapy, chemotherapy, targeted therapy, hormonal treatments, immunotherapy, and recently the antibody-drug conjugates (ADC). All these treatments have more or less consequences for the immune system of our patients, above the cancer itself, which causes a state of immunosuppression.
(BELG J MED ONCOL 2025;19(2):61–62)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
